24 patents
Utility
A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease
27 Jul 23
The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) encoding a spike (S) protein or a part thereof, such as a receptor-binding domain (RBD), and additional antigenic sequences derived from other proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19).
Jürgen Hausmann, Robin Steigerwald, Matthias Habjan, José Medina Echeverz, Stephan Rambichler
Filed: 10 Jun 21
Utility
Conditions Improving Poxvirus Stability
13 Apr 23
The present invention relates to aqueous compositions conferring improved stability to poxvirus during storage as well as to the use of such compositions and methods for preparing the same.
Katrine Kjaer, Markus Kalla
Filed: 12 Mar 21
Utility
Medical Uses of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA)
23 Feb 23
The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) expressing a TAA and the costimulatory molecule 4-1BBL for use in (i) the prevention of recurrence of a solid tumor, wherein the recombinant MVA is intratumorally administered to the solid tumor, or (ii) the treatment, prevention and/or prevention of recurrence of a tumor, wherein the recombinant MVA is intratumorally administered to another solid tumor.
Maria Hinterberger, José Medina Echeverz, Mathias Habjan, Jügen Hausmann, Markus Kalla
Filed: 20 Nov 20
Utility
Combination Therapy for Treating Cancer With an Antibody and Intravenous Administration of a Recombinant MVA
11 Aug 22
The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient.
Hubertus HOCHREIN, Henning LAUTERBACH, José MEDINA ECHEVERZ, Matthias HABJAN
Filed: 14 Mar 22
Utility
Methods and Compositions for Inducing Protective Immunity Against Filovirus Infection
24 Mar 22
The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER, Maria Grazia PAU, Benoit Christophe Stephan CALLENDRET, Lucy A. WARD
Filed: 11 Oct 21
Utility
Poxvirus Vectors Encoding HIV Antigens, and Methods of Use Thereof
24 Mar 22
Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided.
Frank Wegmann, Johannes Petrus Maria Langedijk, Jerôme Hubertina Henricus Victor Custers, Viki Bockstal, Markus Kalla
Filed: 10 Dec 21
Utility
Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40L
6 Jan 22
The invention relates to a composition and related methods for reducing tumor volume and/or increasing the survival of a cancer patient.
Henning Lauterbach, Maria Hinterberger, José Medina Echeverz
Filed: 20 Nov 19
Utility
Recombinant Modified Vaccinia Virus Ankara (MVA) Foot and Mouth Disease Virus (FMDV) Vaccine
23 Dec 21
The present invention relates to modified poxviral vectors and to methods of making and using the same.
Robin Steigerwald, Markus Kalla
Filed: 30 Aug 21
Utility
Compositions and Methods for Enhancing the Stability of Transgenes in Poxviruses
4 Nov 21
Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses.
Markus Kalla, Ryan Rountree, Ulrike Dirmeier
Filed: 5 Jul 21
Utility
Methods and Compositions for Enhancing Vaccine Immune Responses
30 Sep 21
Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a CD40 ligand (CD4OL) and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increases T-cell immune responses specific for the heterologous disease-associated antigen when administered to a human host, and related methods and uses.
Henning Lauterbach, Hubertus Hochrein
Filed: 11 Apr 21
Utility
Methods and Compositions for Inducing an Immune Response Against Hepatitis B Virus (HBV)
2 Sep 21
Provided herein are Modified Vaccinia Ankara (MVA) vectors and adenovirus vectors encoding HBV antigens.
Daniel BODEN, Helen HORTON, Jean-Marc Edmond Fernand Marie NEEFS, Soumitra ROY, Jerôme Hubertina Henricus Victor CUSTERS, Roland Christian ZAHN, Markus KALLA
Filed: 18 May 21
Utility
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor
8 Jul 21
The present disclosure encompasses therapies, compositions, and methods for treatment of a human cancer patient using a recombinant poxvirus encoding a tumor-associated antigen in combination with one or more agonists or antagonists of immune checkpoint inhibitors.
Susan Foy, Stefanie Mandl, Ryan Rountree, Alain Delcayre
Filed: 18 Mar 21
Utility
Recombinant Modified Vaccinia Virus Ankara (MVA) Equine Encephalitis Virus Vaccine
8 Jul 21
The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same.
Robin Steigerwald, Markus Kalla
Filed: 4 Jan 21
Utility
Recombinant Modified Vaccinia Virus Ankara (MVA) Respiratory Syncytial Virus (RSV) Vaccine
1 Jul 21
Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses.
Cedric Cheminay, Robin Steigerwald, Paul Chaplin
Filed: 15 Mar 21
Utility
Storage Improved Poxvirus Compositions
24 Jun 21
The present invention provides storage optimized aqueous compositions comprising a poxvirus suitable as poxvirus vaccine and pharmaceutical compositions, in particular liquid compositions or liquid frozen compositions, and methods of making them.
Katrine Kjaer, Kerstin Mammeri
Filed: 6 Sep 19
Utility
Compositions and Methods for Inducing an Enhanced Immune Response Using Poxvirus Vectors
14 Oct 20
Provided herein are recombinant poxviruses comprising heterologous or native nucleic acids specifying excess double-stranded RNA (dsRNA) early in infection, which may further comprise heterologous nucleic acids encoding one or more costimulatory molecules, and/or heterologous nucleic acids encoding one or more infectious disease-associated antigens or tumor-associated antigens, as well as pharmaceutical compositions comprising such recombinant poxviruses and methods and uses thereof.
Jürgen Hausmann, Michael Wolferstätter
Filed: 10 Apr 20
Utility
Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Antibody
30 Sep 20
The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient.
Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
Filed: 22 Aug 18
Utility
Recombinant Modified Vaccinia Virus Ankara (MVA) Filovirus Vaccine
26 Aug 20
The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses.
Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann
Filed: 26 Feb 20
Utility
Stable Virus-containing Composition
24 Jun 20
Described herein are compositions and pharmaceutical compositions including poxviruses, in particular vaccinia virus such as modified vaccinia Ankara (MVA) virus, a sulfate salt at a concentration between about 5 mM and 300 mM and a buffer, wherein the composition has a pH of between about 6.0 and 8.5.
Ahmad Shakeb SEDIQ, Wouter Frank TONNIS, Martinus Anne Hobbe CAPELLE
Filed: 14 May 18
Utility
Recombinant Modified Vaccinia Virus Ankara (MVA) Respiratory Syncytial Virus (RSV) Vaccine
3 Jun 20
Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses.
Cédric Cheminay, Robin Steigerwald, Paul Chaplin
Filed: 8 Jan 20